Short Report: Treatment Insulin degludec improves glycaemic control with lower nocturnal hypoglycaemia risk than insulin glargine in basal–bolus treatment with mealtime insulin aspart in Type 1 diabetes (BEGIN® Basal–Bolus Type 1): 2-year results of a randomized clinical trial

AIMS: The goal of this study was to compare the long-term safety and efficacy of the basal insulin analogue, insulin degludec with insulin glargine (both with insulin aspart) in Type 1 diabetes, over a 2-year time period. METHODS: This open-label trial comprised a 1-year main trial and a 1-year exte...

Descripción completa

Detalles Bibliográficos
Autores principales: Bode, B W, Buse, J B, Fisher, M, Garg, S K, Marre, M, Merker, L, Renard, E, Russell-Jones, D L, Hansen, C T, Rana, A, Heller, S R
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BlackWell Publishing Ltd 2013
Materias:
Research Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4264937/
https://www.ncbi.nlm.nih.gov/pubmed/23710902
http://dx.doi.org/10.1111/dme.12243

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4264937/
https://www.ncbi.nlm.nih.gov/pubmed/23710902
http://dx.doi.org/10.1111/dme.12243

Ejemplares similares